ALLO-501A Ph2 Trial Likely to Include a Consolidation Regimen and Outpatient Administration; CD52 LD Regimens May Require Educational Outreach to Increase ALLO-501A Adoption; Allogene’s CD19 Forum Summary
On Wednesday, May 19, Allogene held their CD19 forum (presentation / webcast) ahead of ASCO 2021 and presented updated clinical data from their ALLO-501 (CD19 CAR-T) program. Of note, Allogene discussed results from a survey assessing physicians’ CAR-T preferences in r/r LBCL. Below, Celltelligence provides insights on ALLO-501’s efficacy and safety profile and how it compares to currently approved CD19 CAR-Ts. Furthermore, Celltelligence comments on Allogene’s survey discussing the main factors that HCPs may consider when selecting allogeneic CAR-Ts over autologous therapies.
About The Author
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
You’ll be able to access the full article from your Celltelligence Library after signing up.